Humacyte, Inc. (HUMA) Dividend History

Company News

• US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert

  US stock futures are trading lower after a three-day advance, as investors react cautiously to President Trump's mixed tariff signals. The market is looking more balanced, having moved from 'above-trend to on-trend', according to an expert.

  Benzinga

  Featured Companies: CISO GME QQQ SPY THTX WINT
• DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

  The Law Offices of Frank R. Cruz has filed class action lawsuits on behalf of shareholders of Wolfspeed, Humacyte, Xerox, and Zeta Global Holdings. The lawsuits allege that the companies made materially false and/or misleading statements about their business, operations, and prospects.

  GlobeNewswire Inc.

  Featured Companies: WOLF XRX ZETA
• HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm

  Humacyte, Inc. is facing a securities fraud lawsuit for allegedly making false and misleading statements about its manufacturing practices and the FDA's review of its Biologic License Application.

  Benzinga
• HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

  Humacyte, Inc. (NASDAQ: HUMA) is facing a securities class action lawsuit due to alleged false and/or misleading statements about its manufacturing practices and the potential delay in FDA approval of its product.

  GlobeNewswire Inc.
• Humacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

  Investors who lost money on Humacyte, Inc. (HUMA) have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that the company failed to disclose issues with its manufacturing facility and the potential impact on FDA approval.

  Benzinga